首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1378576

化療引起的血小板減少性疾病治療藥物市場：依藥物類別、依藥途徑、通路和地區

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2023年09月29日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球化療引起的血小板血小板減少性疾病治療市場估計為15.313億美元，預計在預測期內（2023-2030年）年複合成長率為5%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	15.313 億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	5.00%	2030年市場規模預測	21.546 億美元

圖 1. 2023 年化療引起的血小板血小板減少性疾病藥物的全球市場佔有率(%)（依藥物類別）

化療引起的血小板減少性疾病(CIT) 是一種常見病理，與癌症患者化療給藥減少、治療中斷、出血併發症和不良結局有關。目前，CIT的預防和管理尚無明確的指引。為了應對這一課題，血小板生成素 (TPO) 替代療法已被開發並採用作為透過刺激巨核細胞生成和促進血小板生成來解決 CIT 的方法。儘管血小板輸注是治療癌症患者嚴重CIT 的主要方法，但仍有相當大的需求未被滿足。這些包括持續高出血率以及需要調整劑量或延遲給藥。

市場動態

用於治療化療引起的血小板血小板減少性疾病的研發線產品的增加預計將推動市場成長。例如，Nplate（Amgen）是一種血小板生成素受體促效劑（TPO-RA）。用於治療化療引起的血小板減少性疾病(CIT) 的 3 期試驗正在進行中。處於階段臨床試驗中並有可能獲得監管部門核准的主要候選藥物數量不斷增加，這為藥品製造商將治療 CIT 的新藥推向市場提供了重要機會。例如，2020年10月19日，血液和血液疾病研究所醫院啟動了一項單臂試驗，以評估艾曲波帕治療化療引起的血小板血小板減少性疾病的安全性和有效性。該研究正處於第二階段，預計將於 2023 年 12 月完成。

本次調查的主要特點

本報告對全球化療引起的化療血小板減少性疾病治療市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030年）的市場規模和復合年度（年複合成長率）。
本報告揭示了各個區隔市場的潛在收益成長機會，並為該市場說明了一系列有吸引力的投資提案。
本報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
根據公司亮點、產品系列、主要亮點、業績和策略等參數對全球化療引起的化療血小板減少性疾病治療市場的主要參與者進行了分析。
本研究涵蓋的主要企業包括安進公司、諾華公司、輝瑞公司、瑞典Orphan Biovitrum AB、江蘇恆瑞醫藥有限公司、梯瓦製藥工業有限公司和Mylan NV。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
全球化療引起的血小板血小板減少性疾病治療藥物市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球化療引起的血小板血小板減少性疾病治療藥物市場的各種策略矩陣，將有助於相關人員做出決策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 1,531.3 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.00%	2030 Value Projection:	US$ 2,154.6 Mn

Chemotherapy-induced Thrombocytopenia (CIT) is a prevalent medical condition associated with reduced chemotherapy doses, treatment interruptions, bleeding complications, and unfavorable outcomes in cancer patients. Currently, there exists a lack of well-defined guidelines for the prevention and management of CIT. In response to this challenge, thrombopoietin (TPO) replacement therapy has been developed and employed as an approach to address CIT by stimulating the production of megakaryocytes and expediting platelet generation. Despite platelet transfusions being the primary approach to managing severe CIT in cancer patients, there remain substantial unmet needs. These include persistently high rates of bleeding events and the necessity for adjustments or delays in anticancer therapy dosages.

Market Dynamics

The increasing number of pipeline products for the treatment of chemotherapy-induced thrombocytopenia is expected to drive the market growth. For instance, Nplate (Amgen Inc.) is a thrombopoietin receptor agonist (TPO-RA). It is being investigated in phase 3 for the treatment of chemotherapy-induced thrombocytopenia (CIT).

Thus, rising number of lead candidates in late phase clinical trial having the potential to gain regulatory approval is providing robust opportunities for pharmaceutical manufacturers to launch novel drugs for the treatment of CIT.

For instance, on October 19, 2020, Institute of Hematology & Blood Diseases Hospital initiated the single-arm study to evaluate the safety and efficacy of eltrombopag to treat chemotherapy-induced thrombocytopenia. The study is under Phase II trial and is expected to complete by December 2023.

Key features of the study:

This report provides an in-depth analysis of the global chemotherapy-induced thrombocytopenia therapeutics market and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Amgen, Inc., Novartis AG, Pfizer Inc., Swedish Orphan Biovitrum AB, Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chemotherapy-induced thrombocytopenia therapeutics market

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Detailed Segmentation:

By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- Amgen, Inc.
- Novartis AG
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
- Jiangsu HengRui Medicine Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trend
Key Developments
Regulatory Scenario
PEST Analysis
Pipeline Analysis
Acquisition and Collaboration Scenario

4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - COVID-19 Impact Analysis

COVID-19 Epidemiology
Overall Impact on the Healthcare Sector
Total Impact of COVID-19 on the Global Chemotherapy-induced Thrombocytopenia Therapeutics Market
Supply and Demand Analysis

5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

8. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Heat Map Analysis
Company Profiles
- Amgen, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Swedish Orphan Biovitrum AB
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Jiangsu HengRui Medicine Co., Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Mylan N.V.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

化療引起的血小板減少性疾病治療藥物市場：依藥物類別、依藥途徑、通路和地區

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

市場動態

目錄

第1章調查目的和假設

第2章市場展望

第3章市場動態、法規及趨勢分析

第4章全球化療-血小板減少性疾病治療藥物市場-新型冠狀病毒感染疾病（COVID-19）的影響分析

第5章全球化療引起的血小板減少性疾病治療藥物市場，依藥物類別，2018-2030

第6章全球化療引起的血小板減少性疾病治療藥物市場，依給藥途徑，2018-2030

第7章全球化療引起的血小板減少性疾病治療藥物市場，依配銷通路，2018-2030

第8章 2018-2030年全球化療引起的血小板減少性疾病治療藥物市場（依地區）

第9章競爭形勢

第10章章

Market Dynamics

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - COVID-19 Impact Analysis

5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2018-2030, (US$ Mn)

6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2018-2030, (US$ Mn)

7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)

8. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2018-2030, (US$ Mn)

9. Competitive Landscape

10. Section

化療引起的血小板減少性疾病治療藥物市場：依藥物類別、依藥途徑、通路和地區

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

市場動態

目錄

第1章 調查目的和假設

第2章 市場展望

第3章 市場動態、法規及趨勢分析

第4章 全球化療-血小板減少性疾病治療藥物市場-新型冠狀病毒感染疾病（COVID-19）的影響分析

第5章 全球化療引起的血小板減少性疾病治療藥物市場，依藥物類別，2018-2030

第6章 全球化療引起的血小板減少性疾病治療藥物市場，依給藥途徑，2018-2030

第7章 全球化療引起的血小板減少性疾病治療藥物市場，依配銷通路，2018-2030

第8章 2018-2030年全球化療引起的血小板減少性疾病治療藥物市場（依地區）

第9章 競爭形勢

第10章 章

Market Dynamics

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - COVID-19 Impact Analysis

5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2018-2030, (US$ Mn)

6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2018-2030, (US$ Mn)

7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)

8. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2018-2030, (US$ Mn)

9. Competitive Landscape

10. Section

第1章調查目的和假設

第2章市場展望

第3章市場動態、法規及趨勢分析

第4章全球化療-血小板減少性疾病治療藥物市場-新型冠狀病毒感染疾病（COVID-19）的影響分析

第5章全球化療引起的血小板減少性疾病治療藥物市場，依藥物類別，2018-2030

第6章全球化療引起的血小板減少性疾病治療藥物市場，依給藥途徑，2018-2030

第7章全球化療引起的血小板減少性疾病治療藥物市場，依配銷通路，2018-2030

第9章競爭形勢

第10章章